Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493568 | 0.84 | CACNA2D1 (0.52) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A2 | |
| SCHEMBL493178 | 0.84 | CACNA2D1 (0.61) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A2 | |
| SCHEMBL13294172 | 0.82 | HTR6 (0.38) | HTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14148352 | 0.75 | OPRM1 (0.42) | CACNA2D1CACNA1BCACNB1HTR6SLC6A2 | |
| SCHEMBL10460455 | 0.74 | HTR6 (0.50) | HTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19528703 | 0.73 | MC4R (0.64) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL10461245 | 0.73 | HTR6 (0.49) | HTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3396087 | 0.73 | CACNA2D1 (0.55) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A2 | |
| SCHEMBL3395013 | 0.72 | CACNA2D1 (0.57) | CACNA2D1CACNA1BCACNB1CACNA1CSLC6A2 | |
| SCHEMBL2792351 | 0.72 | CACNA2D1 (0.54) | CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | CACNA2D1 638/4885CACNA1B 1416/4885CACNB1 3167/4885 |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | CACNA2D1 1158/4885CACNA1B 279/4885CACNB1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.